Dr. Hamlin on Key Points of a Study on Cerdulatinib in Non-Hodgkin Lymphoma

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a phase II study investigating cerdulatinib in patients with non-Hodgkin lymphoma.

There is an increasing amount of oral agents that will be available for patients with a good safety margin and the possibility of combinations, states Hamlin.

According to Hamlin, we are entering an era where the understanding of biology will allow us to address the patients